Etomidate (USAN, INN, BAN) (marketed as Amidate) is a short-acting intravenous anaesthetic agent used for the induction of general anaesthesia and sedation for short procedures such as reduction of dislocated joints, tracheal intubation, and cardioversion.
CAT No: 10-101-136
CAS No:33125-97-2 (net)
Synonyms/Alias:1-[(1R)-1-Phenylethyl]-1Himidazole-5-carboxylic acid ethyl ester; (+)-Ethyl 1-(α-methyl-benzyl)-imidazole-5-carboxylate
Etomidate is an imidazole-derived compound recognized for its potent activity as a GABA-A receptor modulator and its unique profile among general anesthetic agents. As a non-barbiturate hypnotic, it is widely utilized in neuropharmacological research due to its rapid onset of action and minimal impact on cardiovascular stability. Its molecular structure enables selective modulation of synaptic transmission, making it a valuable tool for studies investigating central nervous system function, receptor pharmacology, and the mechanisms underlying anesthesia. The compound's distinctive interaction with neurotransmitter systems provides a versatile platform for exploring both fundamental and applied aspects of neurobiology.
Neuropharmacology research: Etomidate serves as a reference compound in the study of GABAergic neurotransmission and the pharmacodynamics of intravenous anesthetics. Researchers employ it to dissect the molecular mechanisms by which GABA-A receptor agonists induce central nervous system depression. Its well-characterized action on specific receptor subtypes allows for detailed investigations into synaptic inhibition, receptor desensitization, and ion channel modulation, supporting the development of new hypotheses regarding anesthetic mechanisms at the molecular level.
Receptor binding and structure-activity studies: The compound is frequently used in ligand binding assays and site-directed mutagenesis experiments to map the allosteric and orthosteric sites of GABA-A receptors. By examining the binding affinities and modulatory effects of etomidate analogues, scientists gain insights into the structural determinants of receptor sensitivity and selectivity. Such studies are critical for guiding rational drug design and for understanding the nuanced interactions between anesthetic agents and their molecular targets.
Electrophysiological applications: In vitro and ex vivo electrophysiological recordings utilize etomidate to characterize its effects on neuronal excitability and synaptic transmission. Patch-clamp and field potential techniques enable researchers to quantify changes in membrane currents and synaptic responses, elucidating the compound's influence on neuronal circuit dynamics. These approaches are essential for mapping the neural correlates of anesthesia and for differentiating the actions of various central nervous system depressants.
Comparative anesthetic profiling: The compound is a benchmark agent in comparative studies evaluating the efficacy, safety, and side-effect profiles of experimental anesthetics. By serving as a standard in animal models and in vitro systems, it facilitates the assessment of novel compounds' pharmacological properties relative to an established reference. Such comparative analyses are instrumental in preclinical drug development, informing the selection and optimization of candidate molecules for further investigation.
Toxicology and safety pharmacology: Etomidate is incorporated into toxicological screening protocols to evaluate its potential off-target effects, metabolic pathways, and interaction with cytochrome P450 enzymes. These studies provide essential data on compound stability, biotransformation, and the risk of adverse reactions in research settings. Toxicology assessments also help delineate the boundaries of safe handling and experimental use, ensuring that laboratory protocols remain compliant with best practices in chemical safety and risk management.
This review focuses on the unique clinical and molecular pharmacology of etomidate. Among general anesthesia induction drugs, etomidate is the only imidazole, and it has the most favorable therapeutic index for single bolus administration. It also produces a unique toxicity among anesthetic drugs-- inhibition of adrenal steroid synthesis that far outlasts its hypnotic action and that may reduce survival of critically ill patients. The major molecular targets mediating anesthetic effects of etomidate in the central nervous system are specific γ-aminobutyric acid type A receptor subtypes. Amino acids forming etomidate binding sites have been identified in transmembrane domains of these proteins. Etomidate binding site structure models for the main enzyme mediating etomidate adrenotoxicity have also been developed. Based on this deepening understanding of molecular targets and actions, new etomidate derivatives are being investigated as potentially improved sedative-hypnotics or for use as highly selective inhibitors of adrenal steroid synthesis.
Forman, S. A. (2011). Clinical and molecular pharmacology of etomidate. Anesthesiology: The Journal of the American Society of Anesthesiologists, 114(3), 695-707.
Etomidate is an intravenous anesthetic agent released for clinical use in the United States in 1972. Its popularity in clinical practice is the result of its beneficial effects on intracerebral dynamics with limited effects on hemodynamic function. These properties have made it a safe and effective anesthetic induction agent in both adult and pediatric patients with altered myocardial performance, congenial heart disease, or hypovolemia. However, recent concern has been expressed regarding its effects on the endogenous production of corticosteroids and the impact of that effect on patient outcomes. The following manuscript reviews clinical reports regarding etomidate use in the pediatric population and discusses recent concerns regarding its effects on corticosteroid metabolism and the implications of such effects for clinical use.
Tobias, J. D. (2015). Etomidate in pediatric anesthesiology: Where are we now?. Saudi journal of anaesthesia, 9(4), 451.
3. The spatiotemporal control of signalling and trafficking of the GLP-1R
4. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More